Skip to content
value.today
Cellectis S.A. logo

Cellectis S.A.

ALCLS.PA
$216 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$73 M
For year ending December-2025
Net income
$-68 M
-92.7% margin
SEC filing
Employees
—

Cellectis S.A. in brief

Cellectis S.A. is a listed company in the Biotechnology industry, based in Paris, France. Its last known market value was $216 M (January 2024); there is no current figure. In the year to December 2025 it had sales of $73 M and a net loss of $68 M. By market, the largest shares of its 2025 sales came from France (100%). Its shares trade under the symbol ALCLS.PA (EURONEXT).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

Cellectis S.A. timeline

1 events, 2015
  1. 2015
  2. 🔔
    · approximate
    Initial public offering on EURONEXT

Events of Cellectis S.A. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$341 M$682 M$1.0 B$1.4 B20202021202220232024

World rank over time

▼ down 8,757 places since 2020
2020-01-01: #8746#8,74620202021-01-01: #7016#7,01620212022-01-07: #15479#15,47920222022-12-25: #21987#21,98720222023-07-30: #20775#20,77520232024-01-05: #17503#17,5032024

Rank in France: #173 (Jan 2020) · #132 (Jan 2021) · #230 (Jan 2022) · #330 (Dec 2022) · #305 (Jul 2023) · #235 (Jan 2024)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-92.7%
Operating margin
-45.3%
Return on equity
-89.1%
Liabilities / assets
76.6%
Revenue growth
+75.8%
R&D / revenue
128.2%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $13M, net income $-79M$13MFY18Fiscal year ending Dec 2019: revenue $15M, net income $-102M$15MFY19Fiscal year ending Dec 2020: revenue $51M, net income $-81M$51MFY20Fiscal year ending Dec 2021: revenue $30M, net income $-114M$30MFY21Fiscal year ending Dec 2022: revenue $19M, net income $-106M$19MFY22Fiscal year ending Dec 2023: revenue $1M, net income $-101M$1MFY23Fiscal year ending Dec 2024: revenue $42M, net income $-37M$42MFY24Fiscal year ending Dec 2025: revenue $73M, net income $-68M$73MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$73M+75.8%$-33M$-68M-92.7%
Dec 2024$42M+5360.5%$-60M$-37M-88.6%
Dec 2023$1M-96.0%$-97M$-101M-13297.4%
Dec 2022$19M-36.8%$-90M$-106M-553.7%
Dec 2021$30M-40.6%$-103M$-114M-376.3%
Dec 2020$51M+236.1%$-42M$-81M-158.8%
Dec 2019$15M+19.3%$-124M$-102M-672.1%
Dec 2018$13M—$-105M$-79M-618.1%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-39M$2M$-42M$-0.67—
Dec 2024$23M$3M$20M$-0.41—
Dec 2023$-25M$1M$-26M$-1.77—
Dec 2022$-87M$2M$-90M$-2.33—
Dec 2021$-105M$19M$-123M$-2.55—
Dec 2020$-80M$44M$-124M$-1.91—
Dec 2019$-69M$13M$-82M$-2.41—
Dec 2018$-68M$5M$-73M$-1.93—

SEC filings

Official filings of Cellectis S.A. with the US Securities and Exchange Commission.

Annual results

Revenue
$73 M
Operating income
$-33 M
Net income
$-68 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$325 M
Total liabilities
$249 M
Total equity
$76 M

As of December-2025

Mutual funds holding Cellectis S.A.#

2 funds hold shares worth $1 M. Since their previous reports 0 added shares and 1 sold, selling $0 M net.
Mutual funds holding Cellectis S.A.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Nomura Healthcare FundDelaware Management Company226,875$1 M—0.09%no changeJun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors223,114$1 M—<0.01%−34%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 2 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Markets and events: Cellectis S.A.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
333,012
0.3% of shares · 2.63 days to cover

Fails to deliver

  • : 6,582 shares at $1.10
  • : 7,056 shares at $1.18
  • : 9 shares at $1.41
  • : 90 shares at $1.43

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Cellectis S.A. scorecard#

Passes 4 of the 12 checks that could be worked out: strongest in growth (2 of 4), weakest in profitability (2 of 5). Fiscal year 2025.

  • Valuationnot known
    • –P/E below its peers' medianNo market cap.
    • –Price to book below its peers' medianNo market cap.
    • –Price to sales below its peers' medianNo market cap.
    • –Free cash flow yield above 5%No market cap.
    • –Earnings yield above the 10-year Treasury yieldNo market cap.
    • –The price assumes slower growth than the last three years'No market cap.
  • Growth2 of 4
    • ✓Revenue grew in the newest year75.8%Revenue up 75.8% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.67 vs -0.41Diluted EPS -0.67 in fiscal 2025 against -0.41 the year before (report's currency).
    • ✓Net income higher than five years earlier-$68 M-$68 M in fiscal 2025 against -$81 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability2 of 5
    • ✗Profitable in the newest year-$68 MNet income -$68 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-45.4%-45.4% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-65.3%-65.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-45.4%-45.4% in fiscal 2025 against -467.8% in 2022.
  • Financial health0 of 2
    • –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-0.7×Operating income -0.7 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year10.7%Diluted shares up 10.7% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueNo market cap.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Cellectis S.A.'s statements, beside the median of Biotechnology.

Cellectis S.A.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-45.4%-60.5%
Net margin-92.7%-68.9%
Return on equity-65.3%-61.0%
Revenue growth75.8%15.8%
Free cash flow margin-57.2%-61.5%

2of 7on the Piotroski tests of financial strength

  • Net loss of $68 million, the 12th loss-making year in a row.
  • Free cash flow was negative: -$42 million.
  • The share count rose 10.7% in the year.
  • Operating income covers the interest bill only -0.7 times.

Cellectis S.A.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Cellectis S.A.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue73420.81930r51r15132545
Cost of revenue000.71.81.8r2.0r112.72.6—
Research and development94918898118r77r92777978
Selling, general and administrative2019171723r23r43474543
Total costs and expenses—109106115142r102r147127126124
Operating income−33−60−97−90−103r−42r−124−105−93−67
Interest and finance income1644211.10.7r1.4r7.06.82.01.6
Interest expense and finance costs512241186.5r16r3.63.8187.1
Income before tax−68−37−116−99−97r−54r−115−88−104−67
Income tax−0.400.40.1r000000
Income from continuing operations−68−37−117−99−97−54−115−88−104−67
Income from discontinued operations008.4−15−28r−44r−115−88r00
Net income including minority interests−68−37−108−114−125−97−115−88−104−67
Minority interests' share of net income00−7.4−7.9−11−16−13−9.6−4.3—
Net income attributable to shareholders−68−37−101−106−114−81−102−79−99−67
Earnings per share, basic-0.67-0.41-1.77-2.33-2.55-1.91-2.41-1.93-2.78-1.91
Earnings per share, diluted-0.67-0.41-1.77-2.33-2.55-1.91-2.41-1.93-2.78-1.91
Shares, weighted average (basic)100915746454342413635
Shares, weighted average (diluted)10091574645—————
Balance sheet
Cash and cash equivalents6214313793r186241341452256255
Receivables146.70.60.8205.23.03.02.83.6
Inventory———001.6r2.90.30.30.1
Other current assets5.45.57.79.19.7301615148.9
Current assets———122225315392488323312r
Property, plant and equipment394655647972248.7r7.217
Right-of-use (leased) assets24303844697446———
Other intangible assets0.51.1————————
Non-current assets889610111715715476139.719
Total assets325384334261382469467501333331
Current liabilities146166155484952634745r56
Lease liabilities (non-current)283443497276471.0——
Non-current liabilities10386947296109493.73.40.6
Total liabilities249253250———————
Retained earnings—————−506−406−327−254r−210r
Shareholders' equity7613185118221284r315409265r273
Minority interests——08.01525r4041191.9r
Total equity7613185126236309355r450284r273r
Total liabilities and equity325384334261382469467501333331
Shares outstanding1001007246454342423635
Cash-flow statement
Depreciation and amortization2020191814r7.8r6.92.43.42.2
Share-based compensation6.13.25.26.011r10r27375059
Cash from operating activities−3923−25−87−105−80r−69−68−52−33
Capital expenditure−2.4−2.6−1.1−2.4−19r−44r−13−4.7−2.4−14
Intangible assets bought−1.2−1.30−0.0−0.0−0.3r−0.0−0.2−0.3−0.3
Cash from investing activities−29−103−16−2.87.3−54−36361.8−53
Debt issued023305.80—————
Debt repaid−5.4−5.0−5.1−1.30—0−0.1−0.0−0.1
Shares issued———−0.645—01862.90.7
Cash from financing activities−1789831.14827r−3.9236410.5
Exchange-rate effect on cash3.9−2.80.9−3.4−5.87.9r−2.1−8.911−2.2
Change in cash−869.343−89−50−107r−109204−9.3−85
Report20-F20-F20-F20-F20-F20-F20-F20-F20-F20-F

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2025. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Cellectis S.A. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

How Cellectis S.A. compares in Biotechnology

  • Revenue$73 M · higher than 65% of 647
  • Net margin-92.7% · higher than 42% of 408
  • Revenue growth75.8% · higher than 80% of 438

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Cellectis S.A.🇫🇷$216 M—-92.7%+75.8%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 16, 2026

Figures from SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Cellectis S.A.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Cellectis S.A.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Cellectis S.A.? Suggest a correction